2° International Scientific Advisory Board 2015AB November 4, 2020



ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO

Discovery in Immuno-oncology

Paola Nisticò M.D. UOSD Tumor Immunology and Immunotherapy

European Regional Development Fund Project (POR FESR Lazio): Generation of innovative CAR-T and BiTE for tumor microenvironment immune conversion

Alliance Against Cancer (ACC) WG IMMUNOTHERAPY Immunoscore to identify biomarkers in ICB treated NSCLC patients

UOSD tumor immunology and immunotherapy projects

Institutional projects

Network projects



4thNov2O2O



Immune Monitoring Platform

> UOSD tumor immunology and immunotherapy projects





WORKFLOW





A platform to identify prognostic and theranostic biomarkers and druggable pathways: hMENA splicing as a crucial player in the communication among tumor, CAF, extracellular matrix and immune cells

UOSD tumor immunology and immunotherapy projects



SAB



From the antibody response of a cancer patient a key regulator of actin cytoskeleton dynamics, hMENA and its tissue specific isoforms in cancer



AIRC

hMENA_Δv6



Expression

- Epithelial cells
- Absent in invasive cells Down-regulated by TGFβ1 during EMT
- Function
- Promotes cell-cell adhesion Sustains E-Cadherin expression

Anti-apoptotic

 Pro-proliferative Anti-invasive Reduces ECM components (Fibronectin and MMPs) and MMP activity

Inhibits TGF^{β1} signaling

Inhibits β1 integrin signaling

Relationship to outcome

hMENA-hMENA^{11a} — Favourable outcomes

Expression	Fur
Mesenchymal "like" epithelial cells	• Su
Mesenchymal cells	• Inc
• Over-expressed by TGFB1 during EMT	• In
• Up-regulated by TGFβ1, β-catenin, ET1	an
	۰Pr

oction

stains Vimentin expression creases cell invasiveness vadopodia formation d function omotes TGFB1 induced EMT Increases β1 integrin signaling Increases ECM components

Relationship to outcome hMENA-hMENA∆v6 —► Poor outcomes



Di Modugno et al. Int J Cancer. 2004; Di Modugno et al. Cancer Res 2007; Di Modugno et al. PNAS 2012; Trono et al. Oncogene 2016: Melchionna et al Oncolmmunology 2016: Di Modugno, Spada et al. Oncogene 2018 Melchionna et al. EMBO Rep 2020



Tertiary lymphoid structures localized within the tumor core are predictive of survival in early N0 NSCLC patients

TLS in the Tumor Area (AT)

A I R C



- Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Cabrita R, et al. Nature. 2020
- <u>B cells and tertiary lymphoid structures promote immunotherapy response.</u>Helmink BA, et al. Nature. 2020
- <u>B cells are associated with survival and immunotherapy response in sarcoma.</u>Petitprez F, et al. Nature. 2020



İSAB



Intratumoral tertiary lymphoid structure (TLS) localization is associated with hMENA^{11a} expression in tumor cells, low hMENA/hMENAΔv6 expression in CAFs and low stromal Fibronectin in N0 NSCLC



Francesca Di Modugno Anna Di Carlo

RE



 RNA-SEQ analysis of NSCLC cell lines revealed that depletion of hMENA^{11a} in NSCLC cell lines increased the expression of Fibronectin and reduced the Lymphotoxin beta receptor (LTβR),a crucial molecule in lymphoid tissue organogenesis and maintenance. The depletion of hMENA/hMENAΔv6 in CAFs induces the expression of LTβR, indicating that the pattern of hMENA isoform may contribute to TLS organization and localization

4thNov2O2C

Studies are ongoing to evaluate hMENA isoform expression and TLS localization in tumor tissues of ICB-treated NSCLC patients



Mesenchymal traits resulting from tumor intrinsic and extrinsic factors influence T-cell trafficking and function determining resistance to ICB and CAR-T treatment in solid tumors





SAB

The actin modulator hMENA regulates GAS6-AXL axis and pro-tumor cancer/stromal cell cooperation





Roberta Melchionna

A I R C

- CAFs with a pro-tumor activated state express higher levels of hMENA/hMENADv6 compared to normal fibroblasts.
- CAFs over-expressing hMENADv6 secrete GAS6 and favor the invasiveness of AXL- expressing PDAC and NSCLC cells.
- Reciprocally in tumor cells hMENA/hMENADv6 regulate AXL expression, and sustain GAS6-AXL paracrine axis.
- A high hMENA/GAS6/AXL gene expression signature identifies PDAC and NSCLC patients with a poor prognosis.







Network projects



ÍRE

4thNov2O2C

Identification of novel TME-derived targets suitable for CAR T cell therapy



Immunosuppressive barriers present in the solid tumor microenvironment that can hamper the efficacy of CAR T cell therapy

- Lack of CAR-T cell trafficking in the tumor site
- Presence of CAF and a dense extracellular matrix
- An immunosuppressive TME inhibiting T-cell migration, proliferation and functionality
- Heterogeneous expression of tumor-associated antigens





Hypothesis-driven bioinformatics analyses

CAF activation and low presence of CTL in tumor tissues



Lorenzo D'Ambrosio Eleonora Sperandio

Ecm-myCAF immuno-suppressive signature

ASPN, COL3A1, THY1, SFRP2, COL10A1, COL6A3, LRRC17, CILP, GRP, ITGBL1, COL8A1, COL14A1, ADAM12, OLFML2B, ELN, PLPP4, CREB3L1, FBN1, LOXL1, MATN3, LRRC15, COMP, ISLR, P3H1, COL11A1, SEPT11, NBL1, SPON1, SULF1, FNDC1, CNN1, MIAT, MMP23B, CPXM1, FIBIN, P4HA3, GXYLT2, CILP2, P3H4, CCDC80

CTL signature

CD8A, CD8B, GZMA, GZMB, PRF1



Search Q

Research Articles

Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer

Yann Kieffer, Hocine R. Hocine, Géraldine Gentric, Floriane Pelon, Charles Bernard, Brigitte Bourachot, Sonia Lameiras, Luca Albergante, Claire Bonneau, Alice Guyard Karin Tarte, Andrei Zinovyev, Sylvain Baulande, Gerard Zalcman, Anne Vincent-Salomon, and Fatima Mechta-Grigoriou

DOI: 10.1158/2159-8290.CD-19-1384 Published September 2020 (Check for updates

Quartile division and intersection



GO Biological Processes Extra cellular matrix organization

AEBP1,ANXA2,BGN,BMP1,SERPINH1,COL1A1,COL1A2,COL3A1,COL5 L16A1,COMP,VCAN,CCN2,CTSK,FAP,FBN1,FN1,CCN1,ITGB1,ITGB5,L C,COL14A1,ADAM12,MMP23B,P3H4,POSTN,SULF1,SULF2,CREB3L1, A,MARCKS,PFN1,S100A10,TPM1,TPM2,TPM4,ARPC2,PDLIM3,ENAH





4thNov2O2

Supervised Machine Learning



14 CAFpositive CTLnegative (CAFp_CTLn)



29 CAFnegative CTLnegative (CAFn_CTLn)



14 CAFpositive CTLnegative (CAFp_CTLn)

versus 17 CAFnegative CTLpositive (CAFn_CTLp)



ISAB



Preclinical Models

Analysis of immune cell infiltration in the HNSCC murine model and development of oncolytic vectors to be used in combination with the CAR-T treatment.





Preclinical Models 3D bioprint and microfluidic

Printing gradient of stiffness



Harnessing microfluidic channels to precisely control cells and biomaterial deposition, to guide patterning of cells, biomaterials or/and compounds

3D bioprinting and measure of matrix rigidity by Brillouin microscopy





Collaboration with IIT Rome

- 1. Orthotopic Administration of AT-84 luc cells
- 2. Tumor growth and explant
- Organotypic culture

1.14 mm Insert

👫 Gas exchange 🛛 🔲 Culture medium

4.

5.



- Tumor slicing 3.
- Oncolytic virus

exposure

Organotypic slice

- Possible Readouts 6.
- Immunohistochemistry
- Conditioned medium analysis (ELISA)
- Immuno cell profiling
- **RNA** sequencing
- **RNAscope**
- **Digital Spatial Profiling**











Francesca Paolini

Aldo Venuti

Combinationial therapy for CAR-T therapy of solid tumors: CAR-T and oncovirotherapy



Frontiers in Immunology October 2018 | Volume 9 | Article 2460

4thNov2O2C

Oncolytic vectors

Onco Ad5-D24 (24pb deletion in E1A); Onco Ad5-D24-RFP (24pb deletion in E1A, Red Fluorescent Protein); Onco Ad5/3-D24 (24pb deletion, Ad3 knob); Onco Ad5-D24-CpG (24pb deletion CpG islands on backbone); Onco Ad5/3-D24-STING (24pb deletion, Ad3 knob, Stimulator of Interferon Genes)



IHC assessment of the expression of the EGFR as putative target for CAR-T therapy in combination with oncolytic virotherapy in HNSCC





Silvia Baldari



Gabriele Toietta





Network projects



Multi-omics platform to identify biomarkers in ICB-treated NSCLC patients





ALLIANCE AGAINST

CANCER





Retrospective study in ICB-treated NSCLC patients

Tissue samples (n=24) analyzed by the multi-omics platform

Patient ID	Response	Istitution	Year	Sex
Patient_C	GR	IRE	2018	М
Patient_H	GR	IRE	2018	М
ACC_IMM_IRE_GR06_Q	GR	IRE	2019	М
ACCIMMUNO-01	GR	IRE	2019	М
ACCIMMUNO-03	GR	IRE	2019	F
IRE-GR09	GR	IRE	2019	М
ACCIMMUNO-10	GR	IRE	2019	М
Patient_2	GR	ISR	2019	F
Patient_3	GR	ISR	2019	F
Patient_9	GR	ISR	2019	М
HUM-ICH10	GR	HUM	2020	F
HUM-ICH05	GR	HUM	2020	F
HUM-ICH03	GR	HUM	2020	М

Patient ID	Response	Istitution	Year	Sex
Patient_D	FP	IRE	2018	F
Patient_F	FP	IRE	2018	F
Patient_B	FP	IRE	2018	F
ACCIMMUNO-02	FP	IRE	2019	М
ACC_IMM_IRE_FP07_Q	FP	IRE	2019	F
Patient_4	FP	ISR	2019	F
Patient_5	FP	ISR	2019	М
Patient_6	FP	ISR	2019	М
Patient_7	FP	ISR	2019	F
Patient_8	FP	ISR	2019	F
Patient_10	FP	ISR	2019	М

GR

Good Responder at 10 months (n=13)

FP Fast Progressor at 3 months (n=11)



TCR Sequencing Analysis

 Most frequent TCRBV usage in 10 NSCLC tissues











- An Italian repository for a more effective Immune-Checkpoint treatment
- Creation of a multicentric repository / web portal comprehensive of clinical, biological and lifestyle data of 2000 ICB-treated patients in accordance with current guidelines
- ACC network could represent an Italian Task Force and become an excellence reference in the international immunotherapy landscape



Neoadjuvant clinical trial to understand mechanisms of radio-immunotherapy combination in head and neck squamous cancer

Longitudinal immune profiling during radiotherapeutic treatment to define hematological toxicity and to identify new immune related target to combine with radiotherapy in prostate cancer

Institutional projects



SAB



Longitudinal immune profiling during radiotherapeutic treatment to define hematological toxicity and to identify new immune related targets to combine with radiotherapy in prostate cancer



Belinda Palermo



Radiotherapeutic treatment and collected blood samples of 21 enrolled prostatic patients Enrolled pts 21 Analyzed pts 20 Schedule of treatment Number of fraction SBRT Salvage RT 6 30 fx Andjuvant RT 3 30 fx Curative RT 7 20 fx

SBRT	5	5 fx
Salvage RT	6	30 fx
Adjuvant RT	3	30 fx
Curative RT	7	20 fx
Androgen Deprivation Therapy (ADT)		
Yes	7	
No	14	
Treatment machine		
CYBERKNIFE	6	
CLINAC	15	
		Number of blood
		samples
N. of pts with pre-ADT blood sample	6	6
N. of pts with blood sample during treatment (4 TIMING)	21	84
N. of pts with 6 months post-treatment blood samples	20	20
N. of pts with 12 months post-treatment blood samples	12	12





Giulia Campo

Multiparametric flow cytometry of inhibitory receptors, differentiation and functional markers in B, NK cells and T lymphocytes





Neoadjuvant clinical trial to understand mechanisms involved in effectiveness of radio-immunotherapy combination in head and neck squamous cancer



Belinda Palermo



Mariangela Panetta

Flow cytometry

TCR sequencing

Bid Sy

SAB

Digital Pathology

Bio-Plex System



Induction Durvalumab (MEDI4736) & Radiotherapy (RT) for Locally Advanced but Resectable Head and Neck Squamous **Cell Carcinomas: A Pilot Study** 14 PATIENTS WILL BE ENROLLED (UICC stage IV disease limited to T1-3N2-3 or T4N1-3 disease) Treatment schedule and monitoring times DURVALUMAB (MEDI4736, 1500 mg), via IV infusio over 60 minutes MONITORING TIMES RADIOTHERAPY (10 Gy) J SURGERY RADIOTHERAPY ± CHEMOTHERAPY 🚹 🕆 🕆 🖞 0 0000 Days 0 29 to 60 28 1 Л **Tumor biopsies** before treatment Tumor tissues after treatment at surgery IN THE TUMOR: Lymph nodes (omo and controlateral) PBMC collection IN THE PERIPHERAL **BLOOD:** Serum/plasma collection 4thNov2O2O

ACKNOWLEDGMENTS

Tumor Immunology and Immunotherapy Unit

Francesca Di Modugno, Roberta Melchionna, Paola Trono, Anna Di Carlo, Belinda Palermo, Mariangela Panetta, Giulia Campo, Annalisa Tocci, Vittoria Balzano, Giuliana Falasca, Maria Vincenza Sarcone, Gabriele Toietta, Silvia Baldari, Annalisa Antonini, Anna Maria Mileo, Francesca Paolini, Aldo Venuti

Thoracic surgery Franco Facciolo

Medical Oncology II Silvia Carpano

Medical Statistics Isabella Sperduti

Pathology Unit Paolo Visca, Enzo Gallo, Barbara Antoniani

Bioinformatic Lorenzo D'Ambrosio, Eleonora Sperandio, Matteo Pallocca

NGS facility (SAFU unit) Francesca De Nicola, Frauke Goeman, Ludovica Ciuffreda

Radiotherapy Giuseppe Sanguineti, Adriana Faiella, Alessia Farneti

IRE Biobank Simona Di Martino Valentina Laquintana

Regina Elena National Cancer Institute, Rome, Italy





4thNov2

ACC WG Immunotherapy

